TCM
ALAB icon

Thames Capital Management’s Astera Labs ALAB Stock Holding History

Thames Capital Management’s Portfolio ALAB Stock Details ALAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9M Buy
+57,733
New +$15.3M 2.29% 16

Other funds holding ALAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Thames Capital Management's ALAB Position: Q2 2026 in Review

Thames Capital Management opened a new position in Astera Labs (ALAB) in Q2 2026: 57,733 shares worth $27.9M. The stake represents 2.29% of the portfolio and ranks #16 among its holdings.

982 funds tracked by Wall St. Rank hold ALAB as of Q2 2026.

  • Thames Capital Management held 57,733 shares of Astera Labs worth $27.9M as of Q2 2026.
  • Astera Labs was a new Thames Capital Management position in Q2 2026.
  • Astera Labs made up 2.29% of Thames Capital Management's portfolio in Q2 2026, its #16 holding.
  • 982 funds tracked by Wall St. Rank held Astera Labs as of Q2 2026.

Based on Thames Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.